• Wed. May 31st, 2023

Sera Prognostics Announces Industrial Modifications and Actions to Optimize Business enterprise for Marketplace Good results Toward Accelerating Test Adoption and Income


May 26, 2023

Aligning Management Group offered New Refined Industrial Concentrate on Institutions Beginning with Current Appointment of Board Member Zhenya Lindgardt as Interim President and CEO

Engages Top Method Home to Evaluate Most effective Pathways Toward Targeting Enhanced Income Generation at Drastically Decreased Operating Charges

Nadia Altomare Anticipated to Move from Chief Industrial Officer to Consulting Function to Assistance Driving Efficiency and Effectiveness in Our Industrial Invest in Partnership with Our External and Internal Group

SALT LAKE CITY, May perhaps 25, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on enhancing maternal and neonatal wellness by delivering revolutionary pregnancy biomarker details to medical doctors and sufferers, right now announced specific industrial adjustments and plans to optimize its tactic and industrial structure to very concentrate business enterprise activities on accelerating test adoption and income at considerably decreased operating charges.

These plans consist of adjustments to greater align leadership with a new refined industrial concentrate on institutions and price-properly accelerating test adoption and income in advance of upcoming information readouts. This procedure began with the current appointment of Board Member Zhenya Lindgardt, a seasoned business enterprise operator for higher-development organizations, as interim President and CEO, announced on May perhaps 15, 2023.  

Sera Prognostics has also engaged a top tactic residence to rigorously evaluate the greatest pathways toward enhanced income at considerably decreased price to extra broadly commercialize the company’s PreTRM® Test and pipeline of technologies. This evaluation is anticipated to be inclusive of effective market place concentrate and prospective strategic partnerships. As aspect of this procedure, Nadia Altomare is anticipated to move from Chief Industrial Officer to a consulting function to assistance driving efficiency and effectiveness in our industrial devote in partnership with our external and internal group.

The Organization has also created pick headcount reductions at month finish in its industrial organization to greater map existing industrial and promoting charges toward refined concentrate on these possibilities becoming deemed as the most profitable in the close to-term from a test adoption and income generation viewpoint. Sera Prognostics is evaluating other techniques to additional optimize its business enterprise although minimizing operating charges and safeguarding its sturdy balance sheet, which at present affords a sturdy foundation toward realization of the Company’s ambitions outlined right now coupled with targeting enhanced shareholder valuation.

“We are taking decisive and effectively-defined measures to optimize for market place accomplishment offered the macro atmosphere, although also taking into consideration the emerging function we seek to play in establishing our 1st-of-its-sort PreTRM test as a normal of care in safeguarding mothers and babies,” stated Sera Prognostics interim CEO, Zhenya Lindgardt. “When modify is at occasions difficult, we anticipate our actions will prove prosperous in supporting our objective to be The Pregnancy Organization although fostering important development, and we are thankful for our team’s function in building a paradigm shift in pregnancy care to generate greater healthcare outcomes for expectant mothers and their youngsters.”

About Sera Prognostics, Inc.

Sera Prognostics is a top wellness diagnostics corporation devoted to enhancing the lives of females and babies by way of precision pregnancy care. Sera’s mission is to supply early, pivotal pregnancy details to strengthen the wellness of mothers and newborns, resulting in reductions in the charges of healthcare delivery. Sera has a robust pipeline of revolutionary diagnostic tests focused on the early prediction of preterm birth danger and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a doctor the individualized danger of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in females with greater danger. Sera Prognostics is situated in Salt Lake City, Utah.

About Preterm Birth

Preterm birth is defined as any birth prior to 37 weeks’ gestation and is the top bring about of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the final 4 consecutive years, extra than 1 in ten infants is born prematurely. Prematurity is connected with a considerably improved danger of big lengthy-term healthcare complications, like finding out disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can create important charges all through the lives of impacted youngsters. The annual wellness care charges to handle brief- and lengthy-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM® Test

The PreTRM® Test is the only broadly validated, commercially readily available blood-primarily based biomarker test that supplies an early, precise and individualized danger prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are very predictive of preterm birth. The PreTRM® Test permits physicians to recognize, in the course of the weeks 18 by way of 20 of pregnancy, which females are at improved danger for preterm birth and its complications, enabling extra informed, customized clinical choices primarily based on every woman’s person danger. The PreTRM® Test is ordered by a healthcare skilled.

Sera Prognostics, the Sera Prognostics logo, The Pregnancy Organization, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other nations.

Protected Harbor Statement

This press release includes “forward-hunting statements” inside the which means of the Private Securities Litigation Reform Act of 1995, like statements relating to accelerating test adoption and income targeting enhanced income generation at considerably decreased operating charges driving efficiency and effectiveness in our industrial devote upcoming information readouts prospective strategic partnerships additional optimizing the Company’s business enterprise enhanced shareholder valuation establishing the Company’s 1st-of-its-sort PreTRM test as a normal of care fostering important development and the company’s strategic directives below the caption “About Sera Prognostics, Inc.” These “forward-hunting statements” are primarily based on management’s existing expectations of future events and are topic to a quantity of dangers and uncertainties that could bring about actual outcomes to differ materially and adversely from these set forth in or implied by forward-hunting statements. These dangers and uncertainties consist of, but are not restricted to: net losses, money generation, and the prospective need to have to raise extra capital revenues from the PreTRM Test representing substantially all Organization revenues to date the need to have for broad scientific and market place acceptance of the PreTRM Test a concentrated quantity of material buyers our potential to introduce new solutions prospective competitors our proprietary biobank crucial suppliers the COVID-19 pandemic and its prospective lingering influence on our operations, as effectively as the business enterprise or operations of third parties with whom we conduct business enterprise estimates of total addressable market place chance and forecasts of market place development prospective third-celebration payer coverage and reimbursement new reimbursement methodologies applicable to the PreTRM Test, like new CPT codes and payment prices for these codes adjustments in FDA regulation of laboratory-created tests the intellectual home rights safeguarding our tests and market place position and other variables discussed below the heading “Danger Variables” contained in our Final Prospectus on Type S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as effectively as any updates to these danger variables filed from time to time in our Quarterly Reports on Type ten-Q, Annual Reports on Type ten-K, or Present Reports on Type eight-K. All details in this press release is as of the date of the release, and the Organization undertakes no duty to update this details unless necessary by law.

Supply Sera Prognostics, Inc.